Eli Lilly's shares plummeted nearly 10% in premarket trading after the company reported Q3 revenues of $11.4 billion, falling short of analysts' expectations of $12.17 billion, despite a 20% year-over-year growth. The disappointing performance of its GLP-1 portfolio, particularly Zepbound, which generated $1.3 billion in sales against a $1.7 billion forecast, raised concerns about future growth. Analysts suggest that while Mounjaro's sales may struggle, Eli Lilly continues to pursue advancements in Alzheimer's treatment and obesity medications, positioning itself as a significant player in the pharmaceutical industry.
